It seems the company finds itself in a damned if you do, damned if you don't situation about releasing info from the Kevetrin trial.
Somewhere, ( can't remember where or by who) I read that if Cellceutix was seeing positive results they would tell us and since they weren't releasing results the drug must not be working.
Now that they were basically forced to release information some seem to think they are trying to mislead us and should wait till the trial is complete to release any info.
I don't disagree with anything you said except disagreeing with me on the PR point. The company did after all PR a spleen lesion disappearing.
I understand why they PRed the thymoma case, I just don't find it THAT intriguing as it's a very rare disease that seems to respond well to combo SOC treatments as I showed in the chart when I first posted. I know this one doesn't but from a "monetizing K" standpoint the PR didn't do much for me. To each his own.
We are on the same page with regard to releasing data in PRs vs peer reviewed articles and conferences.
I'm well aware of emerging biotechs and the results of releasing data early via PR. Happened with MD Anderson with a stock whose board you were previously a moderator. Not my first rodeo.
Market Data 
Markets 
AI
